Browse Studies — Arctuva

Phase 3

A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based…

NSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLC+4 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT07777822

Phase 2

Olomorasib Plus Pembrolizumab as First-Line Treatment for KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

This clinical trial evaluates the combination of olomorasib and pembrolizumab as a first-line treatment for patients with advanced or metastatic non-small cell…

Lung CancerLung Cancer (NSCLC)Locally Advanced NSCLC+1 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT07639242

Phase 2

A Multi-center Phase II Study of Combining Cabozantinib and Atezolizumab as the 1st Line Therapy for PD-L1 Negative Advanced/Metastatic NSCLC (Cabatezo-1)

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzu…

Lung CancerNSCLC Stage IVMetastatic NSCLC - Non-Small Cell Lung Cancer+1 more

Estimated

~$10 – $7,500

Jun Zhang, MD, PhDNCT05859217